| Literature DB >> 33753733 |
Zhong Yao1,2, Luka Drecun1,3, Farzaneh Aboualizadeh1,2, Sun Jin Kim4, Zhijie Li3, Heidi Wood5, Emelissa J Valcourt5, Kathy Manguiat5, Simon Plenderleith6, Lily Yip6, Xinliu Li7, Zoe Zhong7, Feng Yun Yue8, Tatiana Closas9, Jamie Snider1,2, Jelena Tomic1,2, Steven J Drews10,11, Michael A Drebot5, Allison McGeer7, Mario Ostrowski8, Samira Mubareka6,8, James M Rini2,3, Shawn Owen12,13,14, Igor Stagljar15,16,17,18.
Abstract
Better diagnostic tools are needed to combat the ongoing COVID-19 pandemic. Here, to meet this urgent demand, we report a homogeneous immunoassay to detect IgG antibodies against SARS-CoV-2. This serological assay, called SATiN, is based on a tri-part Nanoluciferase (tNLuc) approach, in which the spike protein of SARS-CoV-2 and protein G, fused respectively to two different tNLuc tags, are used as antibody probes. Target engagement of the probes allows reconstitution of a functional luciferase in the presence of the third tNLuc component. The assay is performed directly in the liquid phase of patient sera and enables rapid, quantitative and low-cost detection. We show that SATiN has a similar sensitivity to ELISA, and its readouts are consistent with various neutralizing antibody assays. This proof-of-principle study suggests potential applications in diagnostics, as well as disease and vaccination management.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33753733 DOI： 10.1038/s41467-021-22102-6
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919